Ftse Mib
35.347,11
-0,18%
DAX
18.695,06
-0,16%
S&P 500
5.301,74
0,09%
NASDAQ
16.683,87
-0,09%
Bitcoin
66.502,70
1,94%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Atea Pharmaceuticals Inc (AVIR) Atea Pharmaceuticals Inc (AVIR) Notizie

AVIR

Atea Pharmaceuticals (AVIR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AVIR
DataOraFonteTitoloSimboloCompagnia
14/05/202422:43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202422:05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
07/05/202413:00GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
29/04/202413:00GlobeNewswire Inc.Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
27/03/202412:00GlobeNewswire Inc.Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsNASDAQ:AVIRAtea Pharmaceuticals Inc
28/02/202422:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
21/02/202413:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
03/02/202403:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
01/02/202422:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/01/202422:05GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
03/01/202413:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
13/11/202313:00GlobeNewswire Inc.Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202322:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202313:00GlobeNewswire Inc.Atea Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:AVIRAtea Pharmaceuticals Inc
02/11/202312:00GlobeNewswire Inc.Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
01/11/202312:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
06/09/202313:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
08/08/202322:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/08/202313:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
21/06/202322:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVIRAtea Pharmaceuticals Inc
15/06/202313:00GlobeNewswire Inc.Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir CombinationNASDAQ:AVIRAtea Pharmaceuticals Inc
12/06/202314:20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
05/06/202322:20GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
30/05/202313:00GlobeNewswire Inc.Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
23/05/202322:05GlobeNewswire Inc.Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202322:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202322:05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/05/202322:05GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
28/04/202322:10Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AVIR

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
STMMI
ST Microelectronics
BIT
LDO
Leonardo
BIT
CPR
Davide Campari
BIT
TIT
Telecom Italia
BIT
FBK
Finecobank
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network